Table 3.

Bilateral lung transplantation, postoperative course, and clinical follow-up in pediatric patients.

Patients #1–12	PAH patients undergoing LuTx N = 12
Bilateral lung transplantation
MCS type during LuTx	VA-ECMO, n = 11; CPB, n = 1
Associated procedures in the same operation	ASD closure on CPB, n = 2
Operation time (cut-suture) – hours (range)	6.6 ± 0.5 (4.6–10.1)
Postoperative course after LuTx
Post-LuTx ECMO-duration – hours (range)	185 (73–363)
Post-LuTx ventilation time on ECMO – hours	40 (17–144)
Post-LuTx ventilation time after ECMO-explantation – hours	2 (0–6)
Tracheostomy (number)	0
ICU stay post-LuTx – days	15 ± 2 (4–32)
In-hospital stay post-LuTx – days	41 ± 4 (21–62)
Clinical follow-up
Lung function post-LuTx
FEV1 3 months post-LuTx (%), n = 11	73 ± 5 (52–106)
FEV1 12 months post-LuTx (%), n = 11	83 ± 6 (57–125)
Impeding rejection, number of steroid pulses	2 ± 0.58 (0–5)
Survival post-LuTx – months (range; % survival)	61 (26–104; 100% survival)
Number of Re-LuTx – n (%)	1 (0.08%)a

Values are presented as mean ± SEM (range). Survival is indicated according to the end of the follow-up (September 1, 2022).

ASD, atrial septal defect; CPB, cardiopulmonary bypass; FEV1, forced expiratory volume in the first second; ICU, intensive care unit; LuTx, lung transplantation; MCS, mechanical circulatory support; VA-ECMO, veno-arterial extracorporeal membrane oxygenation.

^a One patient underwent Re-LuTx due to CLAD 3 31 months after initial LuTx (i.e. after the 2-year follow-up period).